Journal
CHEMISTRY & BIOLOGY
Volume 14, Issue 10, Pages 1186-1197Publisher
CELL PRESS
DOI: 10.1016/j.chembiol.2007.09.006
Keywords
-
Categories
Ask authors/readers for more resources
The two subunits of core binding factor (Runx1 and CBF beta) play critical roles in hematopoiesis and are frequent targets of chromosomal translocations found in leukemia. The binding of the CBF beta-smooth muscle myosin heavy chain (SMMHC) fusion protein to Runx1 is essential for leukemogenesis, making this a viable target for treatment. We have developed inhibitors with low micromolar affinity which effectively block binding of Runx1 to CBF beta. NMR-based docking shows that these compounds bind to CBF beta at a site displaced from the binding interface for Runx1, that is, these compounds function as allosteric inhibitors of this protein-protein interaction, a potentially generalizable approach. Treatment of the human leukemia cell line ME-1 with these compounds shows decreased proliferation, indicating these are good candidates for further development.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available